Outcomes of BTD vs. BCD as initial treatment of renal amyloid light-chain amyloidosis: a retrospective cohort study in China

Objectives To compare the efficacy and safety of bortezomib with thalidomide and dexamethasone (BTD) and bortezomib with cyclophosphamide and dexamethasone (BCD) as the initial treatment for renal amyloid light chain (AL) amyloidosis in Chinese cohort.Methods A cohort of 174 patients with AL amyloid...

全面介紹

書目詳細資料

發表在:	Renal Failure
Main Authors:	Sheng Li, Weiting He, Hok-him Yau, Jianteng Xie, Yaxi Zhu, Xiaojie Chen, Shaogui Zhang, Yifan Zhang, Pengjun Liao, Hui Liu, Liwen Li, Liye Zhong, Wenjian Wang
格式:	Article
語言:	英语
出版:	Taylor & Francis Group 2025-12-01
主題:	Light chain amyloidosis bortezomib cyclophosphamide thalidomide dexamethasone
在線閱讀:	https://www.tandfonline.com/doi/10.1080/0886022X.2025.2453006